BIIB Q4 2021 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.7B-4.2% YoY

Gross Profit

$2.1B75.9% margin

Operating Income

$507M18.5% margin

Net Income

$368M13.5% margin

EPS (Diluted)

$2.50

QoQ Revenue Growth

-1.6%

Cash Flow

Operating Cash Flow

$838M

Free Cash Flow

$770M

Stock-Based Comp.

$59M

Balance Sheet

Total Assets

$23.9B

Total Liabilities

$12.9B

Stockholders' Equity

$10.9B

Cash & Equivalents

$2.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.7B	$2.9B	-4.2%
Gross Profit	$2.1B	$2.4B	-12.2%
Operating Income	$507M	-$331M	+253.3%
Net Income	$368M	$358M	+2.9%

Revenue Segments

MS Product Revenues

$1.5B44%

Fumarate

$611M18%

TYSABRI product

$513M15%

SPINRAZA

$441M13%

Interferon

$378M11%

Geographic Segments

Non-US

$1.2B56%

UNITED STATES

$955M44%